Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Quarterly report · Q3

4886.TEDINET S100SSGE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥48.8bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥47.3bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥5.5bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥5.0bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥5.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥5.2bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥8.5bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥5.4bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥6.5bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥4.2bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥94.9bnat 2023-12-31Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥90.8bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥34.5bnat 2023-12-31Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥60.4bnat 2023-12-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥54.1bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥17.5bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥228.132023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.192023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥148.192022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥64.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥166m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥124m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥103m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥903m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥186m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥43.6bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥48.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥48.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥6.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥196m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥155m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥41m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥26m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥41m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥767m
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.2bn
jpcrp040300-q3r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥417m
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥41.9bn
jpcrp040300-q3r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥47.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥41m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥5.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 328
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember41000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember41000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-41000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember41916000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember5187000000JPY
Net salesPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember196000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember47300000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-41000000JPY
Net salesPrior1YTDDuration47259000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember5418000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember417000000JPY
Operating incomePrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-26000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5809000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-767000000JPY
Operating incomePrior1YTDDuration5041000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember43603000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember5096000000JPY
Revenues from external customersCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember124000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember48824000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration48824000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember41000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember41000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-41000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember43603000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember5096000000JPY
Net salesCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember166000000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember48866000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-41000000JPY
Net salesCurrentYTDDuration48824000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E35791-000PharmaceuticalBusinessReportableSegmentsMember6346000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q3r_E35791-000AnimalHealthBusinessReportableSegmentsMember186000000JPY
Operating incomeCurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember-103000000JPY
Operating incomeCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember6429000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-903000000JPY
Operating incomeCurrentYTDDuration5526000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-09
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第３期第３四半期（自　2023年10月１日　至　2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)あすか製薬ホールディングス株式会社
Company name in english cover pageFilingDateInstantASKA Pharmaceutical Holdings Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　山口　隆
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区芝浦二丁目５番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)（03）5484－8845（代表）

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass